Perspectives on the Risk-Stratified Treatment of Multiple Myeloma

Faith E. Davies, Charlotte Pawlyn, Saad Z. Usmani, Jesus F. San-Miguel, Hermann Einsele, Eileen M. Boyle, Jill Corre, Daniel Auclair, Hearn Jay Cho, Sagar Lonial, Pieter Sonneveld, A. Keith Stewart, P. Leif Bergsagel, Martin F. Kaiser, Katja Weisel, Jonathan J. Keats, Joseph R. Mikhael, Kathryn E. Morgan, Irene M. Ghobrial, Robert Z. OrlowskiC. Ola Landgren, Francesca Gay, Joseph Caers, Wee Joo Chng, Ajai Chari, Brian A. Walker, Shaji K. Kumar, Luciano J. Costa, Kenneth C. Anderson, Gareth J. Morgan

Research output: Contribution to journalReview articlepeer-review

Abstract

The multiple myeloma treatment landscape has changed dramatically. This change, paralleled by an increase in scientific knowledge, has resulted in significant improvement in survival. However, heterogeneity remains in clinical outcomes, with a proportion of patients not benefiting from current approaches and continuing to have a poor prognosis. A significant proportion of the variability in outcome can be predicted on the basis of clinical and biochemical parameters and tumor-acquired genetic variants, allowing for risk stratification and a more personalized approach to therapy. This article discusses the principles that can enable the rational and effective development of therapeutic approaches for high-risk multiple myeloma.

Original languageEnglish (US)
Pages (from-to)273-284
Number of pages12
JournalBlood cancer discovery
Volume3
Issue number4
DOIs
StatePublished - Jul 1 2022

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'Perspectives on the Risk-Stratified Treatment of Multiple Myeloma'. Together they form a unique fingerprint.

Cite this